
Prothena Corporation plc (NASDAQ:PRTA) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the anti-amyloid beta (Aβ) antibody therapy drug candidate PRX012 for the treatment of Alzheimer's disease.
PRX012 is a potential best-in-class, subcutaneous anti-amyloid beta antibody therapy from Prothena, currently in a Phase 1 clinical study for the treatment of Alzheimer's disease.